Celyad Oncology H1 FY26 net loss narrows to €1.2 million; operating loss narrows to €1.2 million
Bitget2026/09/23 19:31- Celyad Oncology posted a net loss of €1.2 million for the first half, narrowing from €3.7 million a year earlier.
- Operating loss narrowed to €1.2 million from €3.7 million, while employee benefit expense fell 71.43% to €0.4 million.
- Other operating expenses dropped 64% to €1 million, and net cash used in operations decreased 54.55% to €1.5 million.
- Cash and cash equivalents stood at €0.1 million at June 30, and a €0.5 million capital increase on July 16 strengthened liquidity.
- The group expects existing cash and cash equivalents to fund operating and capital expenditures into 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analysis: Wall Street Is Not Yet Ready to Short AI in Large Numbers
Overseas capital is aggressively buying US stocks! Net inflows reached $942 billions over the past 12 months, marking a record since 1985.
According to data from the US Department of the Treasury, in the 12 months ending July this year, overseas investors made net purchases of US stocks totaling $942 billion, marking the highest rolling 12-month total since records began in 1985. The net purchases in the second quarter alone reached $426 billion, setting a new single-quarter record. Meanwhile, overseas demand for US Treasuries has noticeably cooled, with purchase volumes falling significantly. As a result, the US is facing higher costs in government debt financing.
RootData: BIO will unlock tokens worth about $1 million in one week
Crypto prices
More
